- Home
- BRLT vs DRRX Comparison
BRLT vs DRRX Comparison
Compare BRLT & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- DRRX
- Stock Information
- Founded
- BRLT 2005
- DRRX 1998
- Country
- BRLT United States
- DRRX United States
- Employees
- BRLT N/A
- DRRX N/A
- Industry
- BRLT Consumer Specialties
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- DRRX Health Care
- Exchange
- BRLT Nasdaq
- DRRX Nasdaq
- Market Cap
- BRLT 22.6M
- DRRX 24.8M
- IPO Year
- BRLT 2021
- DRRX 2000
- Fundamental
- Price
- BRLT $1.46
- DRRX $0.81
- Analyst Decision
- BRLT Hold
- DRRX Buy
- Analyst Count
- BRLT 5
- DRRX 2
- Target Price
- BRLT $2.40
- DRRX $5.00
- AVG Volume (30 Days)
- BRLT 101.1K
- DRRX 34.1K
- Earning Date
- BRLT 03-12-2025
- DRRX 03-26-2025
- Dividend Yield
- BRLT N/A
- DRRX N/A
- EPS Growth
- BRLT N/A
- DRRX N/A
- EPS
- BRLT 0.03
- DRRX N/A
- Revenue
- BRLT $422,161,000.00
- DRRX $8,594,000.00
- Revenue This Year
- BRLT $2.43
- DRRX $54.32
- Revenue Next Year
- BRLT $10.40
- DRRX N/A
- P/E Ratio
- BRLT $49.00
- DRRX N/A
- Revenue Growth
- BRLT N/A
- DRRX N/A
- 52 Week Low
- BRLT $1.25
- DRRX $0.70
- 52 Week High
- BRLT $3.21
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- BRLT 48.74
- DRRX 53.18
- Support Level
- BRLT $1.26
- DRRX $0.71
- Resistance Level
- BRLT $1.42
- DRRX $0.87
- Average True Range (ATR)
- BRLT 0.12
- DRRX 0.05
- MACD
- BRLT 0.02
- DRRX 0.01
- Stochastic Oscillator
- BRLT 28.99
- DRRX 61.88
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. Its sales consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .